Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPRISA 014: Safety and Acceptability of Cabotegravir LA in HIV Uninfected Women
NCT02462772Phase 2Withdrawn
- Sponsor
- CAPRISA
- Start
- Oct 2015
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing Cabotegravir with Placebo (2 arms). Primary endpoint: Number of participants with adverse events at 36 months. Planned start Oct 2015; status: withdrawn.
02
Drugs
cabotegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02462772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02462772.